Subject is a (b)(6) caucasian male (dob (b)(6)) 2.5 weeks post anterior left hip replacement (surgery date (b)(6) 2018) who was discharged on coumadin.Relevant prior medical history includes, prior right hip replacement; prior right knee replacement, and prior left knee replacement, a fibrillation and prostate hyperplasia.No history of past coagulation disorders.Post surgical course complicated by severe diarrhea and urinary retention, due to prostate hyperplasia resulting in a visit to a primary care physician on (b)(6) 2018.Testing revealed a large deep venous thrombosis (dvt) in his right leg as well as acute renal failure due to obstruction (scr = 6.0).Pt was transferred to (b)(6) hosp for treatment that included heparin and catheter insertion.Subject was transitioned to oral eliquis on (b)(6) 2018 and continues to be monitored.Expected discharge is (b)(6) 2018.On (b)(6) 2018, subject's daughter, after receiving the fda recall notice about the roche diagnostics coaguchek systems, checked with the home care agency responsible for her father's care.They confirmed the use of the coaguchek xs system for their in-home care inr testing.The fda recall notice was shared with this organization who indicated they would take action for further use.
|